共 82 条
[1]
Ito K(2014)Prostate cancer in Asian man Nat Rev Urol 11 197-212
[2]
Mohler JL(2014)Prostate cancer, version 2.2014 J Natl Compr Cancer Netw 12 686-718
[3]
Kantoff PW(2008)A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 1986-1992
[4]
Armstrong AJ(2014)Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists Eur Urol 66 1101-1108
[5]
Gittelman M(2008)Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 805-813
[6]
Pommerville P(2012)The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer Jpn J Clin Oncol 42 477-484
[7]
Persson B(1989)A controlled trial Leuprolide with and without Flutamide in prostatic carcinoma N Engl J Med 321 419-424
[8]
Klotz L(1996)A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX combination study group Cancer 78 2164-2169
[9]
Miller K(2012)Increased survival with Enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-1197
[10]
Crawford ED(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 424-433